Payment overview · 2025
General Payments
$434.08
36 reported records · 10 companies
Healthcare provider profile · identity verified
Clara Basco Coutee, FNP
Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner · MARKSVILLE, LA · NPI 1962406884
Verified facts
What the public records show
CMS Open Payments records show Clara Basco Coutee, FNP received $434.08 in general payments during 2025 across 36 reported records.
GlaxoSmithKline, LLC. accounted for 37.4% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 12 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 61 claims for Linzess by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 30 claims for Symbicort by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Trelegy Ellipta by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 74 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Rybelsus by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $162.15 | 37.4% | 21 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $103.31 | 23.8% | 5 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $32.17 | 7.4% | 2 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $27.85 | 6.4% | 2 | 2025 |
| Teva Pharmaceuticals USA, Inc. | Unresolved — no canonical attribution shown | $24.40 | 5.6% | 1 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $20.85 | 4.8% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $19.75 | 4.5% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $15.14 | 3.5% | 1 | 2025 |
| Neurocrine BioSciences, Inc. | Unresolved — no canonical attribution shown | $14.73 | 3.4% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $13.73 | 3.2% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $434.08 | 36 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $162.15 | 21 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $63.95 | 3 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $39.36 | 2 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $38.71 | 6 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $32.17 | 2 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $27.85 | 2 | 2025 |
Source payment records
|
|||||
| UZEDY Normalized: uzedy |
Drug | Teva Pharmaceuticals USA, Inc. | $24.40 | 1 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $20.85 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $19.75 | 1 | 2025 |
Source payment records
|
|||||
| INGREZZA Normalized: ingrezza |
Drug | Neurocrine BioSciences, Inc. | $14.73 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $13.73 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $13.73 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 22 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
61 | 20 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
30 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
74 | 14 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 315 | 82 |
| Amlodipine Besylate | Amlodipine Besylate | 271 | 63 |
| Alprazolam | Alprazolam | 262 | 44 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 250 | 69 |
| Gabapentin | Gabapentin | 249 | 60 |
| Fluticasone Propionate | Fluticasone Propionate | 234 | 79 |
| Pantoprazole Sodium | Pantoprazole Sodium | 200 | 49 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 190 | 54 |
| Levothyroxine Sodium | Levothyroxine Sodium | 190 | 36 |
| Tizanidine Hcl | Tizanidine Hcl | 182 | 49 |
| Potassium Chloride | Potassium Chloride | 179 | 46 |
| Trazodone Hcl | Trazodone Hcl | 169 | 31 |
| Hydrochlorothiazide | Hydrochlorothiazide | 150 | 46 |
| Lisinopril | Lisinopril | 144 | 32 |
| Metformin Hcl | Metformin Hcl | 134 | 34 |
| Diclofenac Sodium | Diclofenac Sodium | 129 | 42 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 126 | 37 |
| Jardiance | Empagliflozin | 126 | 25 |
| Omeprazole | Omeprazole | 123 | 26 |
| Furosemide | Furosemide | 115 | 30 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 115 | 33 |
| Ibuprofen | Ibuprofen | 109 | 37 |
| Pravastatin Sodium | Pravastatin Sodium | 94 | 18 |
| Clopidogrel | Clopidogrel Bisulfate | 86 | 22 |
| Clonazepam | Clonazepam | 85 | 15 |
| Escitalopram Oxalate | Escitalopram Oxalate | 83 | 24 |
| Losartan Potassium | Losartan Potassium | 82 | 23 |
| Meloxicam | Meloxicam | 80 | 23 |
| Ozempic | Semaglutide | 74 | 14 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 74 | 12 |
| Ezetimibe | Ezetimibe | 73 | 22 |
| Montelukast Sodium | Montelukast Sodium | 72 | 23 |
| Metoprolol Succinate | Metoprolol Succinate | 71 | 20 |
| Lorazepam | Lorazepam | 69 | suppressed |
| Allopurinol | Allopurinol | 66 | suppressed |
| Trulicity | Dulaglutide | 66 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 66 | 14 |
| Carvedilol | Carvedilol | 65 | 18 |
| Clonidine Hcl | Clonidine Hcl | 64 | 15 |
| Linzess | Linaclotide | 61 | 20 |
| Eliquis | Apixaban | 60 | 11 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 58 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 57 | 11 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 54 | 13 |
| Mounjaro | Tirzepatide | 53 | 11 |
| Famotidine | Famotidine | 52 | 20 |
| Metoprolol Tartrate | Metoprolol Tartrate | 52 | 15 |
| Azithromycin | Azithromycin | 51 | 38 |
| Methylprednisolone | Methylprednisolone | 51 | 34 |
| Buspirone Hcl | Buspirone Hcl | 49 | 13 |
| Fluoxetine Hcl | Fluoxetine Hcl | 49 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 49 | 13 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 48 | 13 |
| Promethazine Hcl | Promethazine Hcl | 47 | 28 |
| Duloxetine Hcl | Duloxetine Hcl | 46 | 12 |
| Paroxetine Hcl | Paroxetine Hcl | 44 | suppressed |
| Tradjenta | Linagliptin | 44 | suppressed |
| Celecoxib | Celecoxib | 42 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 42 | suppressed |
| Tamsulosin Hcl | Tamsulosin Hcl | 42 | suppressed |
| Amoxicillin | Amoxicillin | 41 | 33 |
| Prednisone | Prednisone | 40 | 23 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 39 | 12 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 39 | 19 |
| Valsartan | Valsartan | 39 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 38 | 16 |
| Mupirocin | Mupirocin | 38 | 21 |
| Donepezil Hcl | Donepezil Hcl | 37 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 36 | suppressed |
| Simvastatin | Simvastatin | 36 | suppressed |
| Cefdinir | Cefdinir | 35 | 25 |
| Sertraline Hcl | Sertraline Hcl | 35 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 33 | suppressed |
| Mirtazapine | Mirtazapine | 32 | suppressed |
| Baclofen | Baclofen | 31 | suppressed |
| Fluconazole | Fluconazole | 30 | 15 |
| Glimepiride | Glimepiride | 30 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 30 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 29 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 28 | suppressed |
| Loperamide | Loperamide Hcl | 28 | suppressed |
| Ramipril | Ramipril | 28 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 27 | suppressed |
| Ibu | Ibuprofen | 27 | 12 |
| Memantine Hcl | Memantine Hcl | 27 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 27 | 12 |
| Ketoconazole | Ketoconazole | 26 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 24 | suppressed |
| Myrbetriq | Mirabegron | 24 | suppressed |
| Ondansetron Odt | Ondansetron | 24 | suppressed |
| Finasteride | Finasteride | 23 | suppressed |
| Levetiracetam | Levetiracetam | 23 | suppressed |
| Phenobarbital | Phenobarbital | 23 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 23 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 23 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 22 | suppressed |
| Colchicine | Colchicine | 21 | suppressed |
| Entresto | Sacubitril/Valsartan | 21 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 21 | suppressed |
| Spironolactone | Spironolactone | 21 | suppressed |
| Risperidone | Risperidone | 20 | suppressed |
| Ammonium Lactate | Ammonium Lactate | 19 | suppressed |
| Bupropion Xl | Bupropion Hcl | 19 | suppressed |
| Torsemide | Torsemide | 19 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 19 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 18 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 18 | suppressed |
| Temazepam | Temazepam | 18 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 18 | suppressed |
| Cephalexin | Cephalexin | 17 | 16 |
| Dicyclomine Hcl | Dicyclomine Hcl | 17 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 17 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 17 | 13 |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 16 | suppressed |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 16 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 16 | suppressed |
| Diazepam | Diazepam | 16 | suppressed |
| Fenofibric Acid | Fenofibric Acid (Choline) | 16 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 16 | suppressed |
| Atenolol | Atenolol | 15 | suppressed |
| Chlorthalidone | Chlorthalidone | 15 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 15 | 14 |
| Lactulose | Lactulose | 15 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 14 | suppressed |
| Nifedipine Er | Nifedipine | 14 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 13 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 13 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 13 | suppressed |
| Estradiol | Estradiol | 13 | suppressed |
| Neomycin-Polymyxin-Hc | Neomycin/Polymyxin B/Hydrocort | 13 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 13 | suppressed |
| Rybelsus | Semaglutide | 13 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 12 | suppressed |
| Januvia | Sitagliptin Phosphate | 12 | suppressed |
| Klor-Con 10 | Potassium Chloride | 12 | suppressed |
| Naproxen | Naproxen | 12 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 12 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 11 | suppressed |
| Carbamazepine | Carbamazepine | 11 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 11 | 11 |
| Methocarbamol | Methocarbamol | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $434.08 · 36 records | GlaxoSmithKline, LLC. | AREXVY, BREZTRI, Cologuard Collection Kit, INGREZZA, OTEZLA, QULIPTA, REPATHA, REXULTI, TRELEGY ELLIPTA, UZEDY, VOQUEZNA, VRAYLAR | 5 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Trelegy Ellipta play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error